SCHEMBL21490330

SCHEMBL21490330

COC(=O)C1Cc2ccc(OC)cc2N1C(=O)OC(C)(C)C

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.47
KYAT1 Q16773 1/20 0.44
KYAT3 Q6YP21 1/20 0.44
AADAT Q8N5Z0 1/20 0.44
ALDH1A1 P00352 1/20 0.44
STS P08842 2/20 0.43
HDAC8 Q9BY41 2/20 0.43
EPHX2 P34913 1/20 0.40
PDE4B Q07343 1/20 0.40
MMP3 P08254 2/20 0.40
MMP1 P03956 2/20 0.40
MMP9 P14780 2/20 0.40
MMP7 P09237 1/20 0.40
LMNA P02545 2/20 0.39
MMP8 P22894 2/20 0.39
NR1H2 P55055 2/20 0.39
MMP13 P45452 1/20 0.39
NR1H3 Q13133 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29442988 1.00 PTPN1 (0.47) PTPN1KYAT1KYAT3AADATALDH1A1
SCHEMBL4999428 0.89 KYAT1 (0.45) KYAT1KYAT3AADATALDH1A1STS
SCHEMBL29442994 0.89 KYAT1 (0.45) KYAT1KYAT3AADATALDH1A1STS
SCHEMBL21447269 0.86 PTPN1 (0.48) PTPN1HDAC8PDE4BMMP3MMP8
SCHEMBL19902536 0.86 PTPN1 (0.48) PTPN1AADATHDAC8PDE4BLMNA
SCHEMBL29442998 0.83 DRD2 (0.51) PTPN1LMNA
SCHEMBL2827018 0.83 DRD2 (0.51) PTPN1LMNA
SCHEMBL2827020 0.83 DRD2 (0.51) PTPN1LMNA
SCHEMBL13170457 0.82 PTPN1 (0.45) PTPN1HDAC8PDE4BNR1H2NR1H3
SCHEMBL21470656 0.82 PTPN1 (0.41) PTPN1ALDH1A1STSHDAC8PDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109689639-B Spirolactams as ROCK inhibitors 百时美施贵宝公司 2022-02-18 CN disclosed
EP-3481817-B1 SPIROLACTAMS AS INHIBITORS OF ROCK BRISTOL MYERS SQUIBB CO (US) 2020-08-19 EP disclosed
EP-3481817-B1 SPIROLACTAMS AS INHIBITORS OF ROCK BRISTOL MYERS SQUIBB CO (US) 2020-08-19 EP disclosed
US-10696674-B2 Spirolactams as inhibitors of ROCK BRISTOL-MYERS SQUIBB COMPANY (US) 2020-06-30 US disclosed
US-10696674-B2 Spirolactams as inhibitors of ROCK BRISTOL-MYERS SQUIBB COMPANY (US) 2020-06-30 US disclosed
US-20190322664-A1 SPIROLACTAMS AS INHIBITORS OF ROCK BRISTOL MYERS SQUIBB CO (US) 2019-10-24 US disclosed
US-20190322664-A1 SPIROLACTAMS AS INHIBITORS OF ROCK BRISTOL MYERS SQUIBB CO (US) 2019-10-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10696674-B2 Spirolactams as inhibitors of ROCK MYLK, ROCK1, MYLK2 PTPN1 172/4885KYAT1 2828/4885KYAT3 3279/4885
US-20190322664-A1 SPIROLACTAMS AS INHIBITORS OF ROCK MYLK, ROCK1, MYLK2 PTPN1 172/4885KYAT1 2828/4885KYAT3 3279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.